Zdenka
Zdenka Brunovska, Hudson, OH US
Patent application number | Description | Published |
---|---|---|
20120040141 | Dimensionally Stable, Leak-Free Graphite Substrate - A method for preparing resin-impregnated graphite articles, including providing a sheet of compressed particles of exfoliated graphite having two major surfaces; impregnating the sheet with a first resin system to form a resin-impregnated sheet; surface treating the resin-impregnated sheet to form at least one structure on at least one of the major surfaces of the sheet to form a surface treated sheet; and treating the sheet with a second resin system. | 02-16-2012 |
Zdenka Douglas, Wahroonga AU
Patent application number | Description | Published |
---|---|---|
20150052713 | DECORATIVE DEVICE, SYSTEM AND PROCESS THEREOF - A decorative device adapted for securing to a shoe lace attached to a shoe, wherein the device includes: a body selected from the following group shapes when viewed from a top view: ovoid, kidney bean, cigar, square, or circular; wherein the device includes at least an upper surface joined a lower surface wherein the lower surface is relatively flat and adapted to engage an upper contacting surface of the shoe, when in use; and wherein the device includes a bore in the direction of the longitudinal axis of the device. | 02-26-2015 |
Zdenka Douglas US
Patent application number | Description | Published |
---|---|---|
20150052713 | DECORATIVE DEVICE, SYSTEM AND PROCESS THEREOF - A decorative device adapted for securing to a shoe lace attached to a shoe, wherein the device includes: a body selected from the following group shapes when viewed from a top view: ovoid, kidney bean, cigar, square, or circular; wherein the device includes at least an upper surface joined a lower surface wherein the lower surface is relatively flat and adapted to engage an upper contacting surface of the shoe, when in use; and wherein the device includes a bore in the direction of the longitudinal axis of the device. | 02-26-2015 |
Zdenka Finder, Rohrenfels DE
Patent application number | Description | Published |
---|---|---|
20090247697 | 2,2'-MDI-BASED ISOCYANATE MIXTURES, POLYISOCYANATE POLYADDITION PRODUCTS PREPARED THEREFROM, PROCESSES FOR MAKING THE SAME AND METHODS FOR THEIR USE - Isocyanate mixtures comprising: (a) NCO prepolymers having an NCO content of 1.5 to 18 wt. %; and (b) 1 to 40 wt. % of monomeric 2,2′-diisocyanatodiphenylmethane, based on the isocyanate mixture; wherein the isocyanate mixture has a total NCO content of from 2 to 22 wt. %; polyisocyanate polyaddition products prepared therefrom; and methods of making the same. | 10-01-2009 |
Zdenka Haskova, King Of Prussia, PA US
Patent application number | Description | Published |
---|---|---|
20080274078 | NOVEL USES - The present invention relates generally to the use of human IL-18 combinations in the treatment of cancers. In particular, the present invention relates to combination of human IL-18 and an anti-CD20 antibody. | 11-06-2008 |
20090035258 | METHODS OF TREATING CANCER BY ADMINISTERING HUMAN IL-18 COMBINATIONS - The present invention relates generally to the use of human IL-18 combinations in the treatment of various forms of solid tumors and lymphomas. In particular, the present invention relates to: (1) combinations of human IL-18 with monoclonal antibodies against antigens that are expressed on the surface of cancer cells; and (2) combinations of human IL-18 with chemotherapeutic agents. | 02-05-2009 |
20100111945 | NOVEL USES - The present invention relates generally to the use of human IL-18 combinations in the treatment of cancers. In particular, the present invention relates to combination of human IL-18 and an anti-CD20 antibody. | 05-06-2010 |
20100196310 | METHODS OF TREATING CANCER BY ADMINISTERING HUMAN IL-18 COMBINATIONS - The present invention relates generally to the use of human IL-18 combinations in the treatment of various forms of solid tumors and lymphomas. In particular, the present invention relates to: (1) combinations of human IL-18 with monoclonal antibodies against antigens that are expressed on the surface of cancer cells; and (2) combinations of human IL-18 with chemotherapeutic agents. | 08-05-2010 |
20130156779 | NOVEL ANTIGEN BINDING PROTEINS - The present disclosure relates to antigen binding proteins, such as antibodies, that bind to HER3, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present disclosure also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with breast cancer, ovarian cancer, prostate cancer, bladder cancer, pancreatic, gastric, melanoma and other cancers that overexpress HER3. | 06-20-2013 |
Zdenka Hradecna, Madison, WI US
Patent application number | Description | Published |
---|---|---|
20100144548 | VECTOR SYSTEMS - The present invention relates generally to the field of molecular biology and genomics. More specifically, the present invention concerns the cloning of nucleic acid molecules and the production of nucleic acid libraries, as well as the expression of recombinant proteins and bactofection. | 06-10-2010 |
Zdenka Jerala-Strukelj, Ljubljana SI
Patent application number | Description | Published |
---|---|---|
20110112160 | TABLET COMPRISING EPROSARTAN MESYLATE - A tablet comprising eprosartan mesylate in only one form of either anhydrous or dihydrate form is described. In another aspect, a tablet is disclosed comprising eprosartan mesylate obtainable by direct compression, wherein eprosartan mesylate is provided in one primary form of being either anhydrous or dihydrate to the extent that the eprosartan mesylate shows a dissolution profile with a variability of dissolution from the different tablet samples of a set of below 30%, preferably below 20% and more preferably below 10% relative standard deviation at all time during dissolution, measured using USP apparatus 2, placing the tablets in 1000 ml 0.1 M hydrochloric acid at 37±0.5° C. with paddle speed of 50 rpm. Further described is a set of samples of tablets, wherein each comprises eprosartan mesylate as an active ingredient, wherein the eprosartan mesylate shows a dissolution profile with a variability of dissolution from different tablet samples of the set of below 30%, preferably below 20% and more preferably below 10% relative standard deviation at all time during dissolution. A tablet can be prepared by using a process, comprising providing eprosartan mesylate in only one primary form of being either anhydrous or dihydrate, optionally subjecting eprosartan mesylate to dry granulation process, and a direct compression while maintaining said only one primary form; or by process comprising mixing eprosartan mesylate in particulate form with excipients or additives, wherein the prepared whole dry formulation or granulation of eprosartan mesylate has a water activity of less than 0.62, preferably less than 0.60 and more preferably less than 0.50, respectively determined at room temperature, and subsequently tabletting. Suitable prophylactic and/or therapeutic uses are also described. | 05-12-2011 |
20110135738 | SINGLE DOSAGE PHARMACEUTICAL FORMULATION COMPRISING EPROSARTAN MESYLATE - A dry formulation or granulation of eprosartan mesylate is described which comprises eprosartan mesylate in particulate form with a particle size, wherein at least 65 v/v % eprosartan mesylate particles fall in a particle size range of from 2 to 27 μm. In another aspect, a dry formulation or granulation of eprosartan mesylate comprises eprosartan mesylate combined with an excipient which at least comprises a PEG having molecular weight in the range of 400 to 20000 and mannitol. Further described is a single dosage pharmaceutical formulation such as tablet obtained from such a dry formulation or granulation of eprosartan mesylate by direct compression or dry granulation. A dry formulation or granulation of eprosartan mesylate, or a process for the preparation thereof is also described, which comprising eprosartan mesylate in particulate form mixed with one or more excipients or additives in a way that a limited water activity is obtained. The dry formulation or granulation of eprosartan mesylate can be directly compressed or processed by dry granulation, while maintaining the eprosartan mesylate in only one stable form. Suitable prophylactic and/or therapeutic uses are also described. | 06-09-2011 |
20120027857 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING O-DESMETHYL-VENLAFAXINE - This invention relates to sustained release pharmaceutical compositions comprising O-desmethyl-venlafaxine, in particular to sustained pharmaceutical compositions comprising O-desmethyl-venlafaxine orotate and/or O-desmethyl-venlafaxine glucuronate. | 02-02-2012 |
20140363505 | NEW COMBINATION - The invention relates to a new fixed dose combination of benazepril with pimobendan. | 12-11-2014 |
Zdenka Jerala-Strukelj, Mavcice SI
Patent application number | Description | Published |
---|---|---|
20080242725 | Pharmaceutical Composition - Stabilized pharmaceutical compositions comprising polymorphs of active pharmaceutical ingredients susceptible to conversion to alternate polymorph forms are prepared by a process of wet granulation in which the ratios of active, fillers, and granulating liquid are controlled in order to avoid polymorphic interconversions. | 10-02-2008 |
20080299193 | Pharmaceutical composition comprising eszoplicone - The present invention relates to a stable pharmaceutical composition of eszopiclone with a defined particle size. | 12-04-2008 |
Zdenka Uhrikova, Bratislava SK
Patent application number | Description | Published |
---|---|---|
20130006689 | METHODS, SOFTWARE, AND SYSTEMS FOR MAINTAINING A SINGLE HIERARCHY OF TASKS ACROSS MULTIPLE PROJECTS AND/OR MULTIPLE TASK MANAGEMENT TOOLS - Schemes providing master list functionality that allows a user to reorder to-do items from across multiple projects and/or multiple project management tools. Such schemes can ensure that whatever project management tools the user and others associated with the various projects are using at any time, changes in their task planning will be reflected both in the master list and across all other projects and project management tools, as needed. The necessary hierarchy is maintained by creating an absolute order between different projects and reflecting changes in task order in both directions. | 01-03-2013 |
Zdenka Zanova, Lisov CZ
Patent application number | Description | Published |
---|---|---|
20130189015 | MULTICOLOR WRITING AND DESIGNING MEANS - A multicolor writing and designing device has an elongated pastel color capsule with a plurality of longitudinal segment groups disposed substantially in parallel with a main capsule axis, at least one segment of a group being located within the capsule such that it forms a capsule tip. At least two of the segment groups are of different tints from the same color sampling zone in a color space colorimetric triangle. having a plurality of such sampling zones. The color sampling zones may correspond to areas in the CIE 1964 10° Standard Observer color space. | 07-25-2013 |